Gate Bioscience Captures $65M Series B to Advance Molecular Gate Protein Degradation Platform

Gate Bioscience secured $65 million in an oversubscribed Series B financing round, bringing its total capital raised to $135 million as of November 13, 20255 7 9 10.

The Series B was led by Forbion, with participation from new investor Eli Lilly, and existing investors including Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV, and ARCH Venture Partners5 7 10.

Gate Bioscience develops 'Molecular Gates', a novel class of oral small molecule medicines that aim to eliminate disease-causing extracellular proteins at their source inside cells5 7 10.

Molecular Gates work by binding to the single secretory channel through which all extracellular proteins exit cells, selectively blocking and degrading disease-related proteins before they reach the bloodstream7 10 3.

The new funding will advance lead programs through IND-enabling studies and into Phase 1 clinical trials, as well as accelerate the discovery of molecular gates targeting additional high-value proteins5 7 10.

Protein elimination is considered an emerging frontier in precision medicine, potentially addressing unmet needs by tackling a broad range of conditions driven by aberrant protein function, misfolding, or production1 5.

Institutional investment in the protein elimination sector reflects growing confidence, though clinical validation of Gate Bioscience’s approach remains a key milestone for the field1.